A detailed history of Marshall Wace, LLP transactions in Allovir, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 324,658 shares of ALVR stock, worth $146,096. This represents 0.0% of its overall portfolio holdings.

Number of Shares
324,658
Previous 324,658 -0.0%
Holding current value
$146,096
Previous $233,000 12.45%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.72 - $0.82 $29,144 - $33,191
-40,478 Reduced 11.09%
324,658 $233,000
Q1 2024

May 15, 2024

BUY
$0.64 - $0.78 $25,905 - $31,572
40,478 Added 12.47%
365,136 $277,000
Q1 2022

May 16, 2022

SELL
$6.75 - $13.52 $20,391 - $40,843
-3,021 Reduced 0.92%
324,658 $2.19 Million
Q4 2021

Feb 14, 2022

BUY
$12.94 - $25.99 $4.24 Million - $8.52 Million
327,679 New
327,679 $4.24 Million
Q2 2021

Aug 13, 2021

SELL
$19.44 - $25.06 $2.97 Million - $3.83 Million
-152,939 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$20.81 - $45.5 $3.01 Million - $6.58 Million
144,715 Added 1759.67%
152,939 $3.58 Million
Q4 2020

Feb 16, 2021

SELL
$23.94 - $46.81 $382,609 - $748,117
-15,982 Reduced 66.02%
8,224 $316,000
Q3 2020

Nov 16, 2020

BUY
$21.05 - $42.7 $509,536 - $1.03 Million
24,206 New
24,206 $666,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $41.9M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.